NEW DELHI, Feb 12: Zydus Lifesciences on Thursday said it will pay USD 120 million to Astellas Pharma to settle a patent litigation over a medication to treat an active bladder.
Zydus Pharmaceuticals USA, Inc USA, a wholly owned subsidiary of the company, has entered into a settlement agreement with Astellas in relation to its drug Myrbetriq, the Ahmedabad-based drug maker said in a regulatory filing.
Under the terms of the settlement agreement Zydus shall pay Astellas an aggregate amount of USD 120 million, it said.
Zydus shall additionally pay a prepaid per unit licensing fee on units of Zydus’ generic Mirabegron sold in the US from the date of Settlement Agreement till September 2027, it added.
“This settlement agreement concludes all litigations between Astellas and the two companies relating to Myrbetriq and Mirabegron and enables Zydus to continue marketing its generic Mirabegron in the US,” the drug maker stated.
Zydus shares were trading 2.20 per cent up at Rs 917.80 apiece on BSE. (PTI)
The post Zydus to pay USD 120 mn to Astellas to settle patent litigation appeared first on Daily Excelsior.